Back to Woodline Partners LP Woodline Partners LP

REGNREGN
Showing 8 of 26 quarters

Position history for Woodline Partners LPWoodline Partners LP's holdings in Regeneron Pharmaceuticals, Inc.

Yes. Woodline Partners holds 72,595 shares of REGN (Regeneron Pharmaceuticals), worth $45.3M, as of its Q2 2026 13F filing. It increased the position by 4,844 shares (+7.2%) from Q1 2026. Woodline Partners has held REGN since Q4 2020, across 23 quarterly 13F filings. REGN is 0.1% of Woodline Partners' reported 13F portfolio.

Current Value

$45.3M

Current Shares

72,595

Total Value Change

-$59.2M

Total Shares Change

-26,822

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
72,595
+7.2%
$45.3M0.1%$622.81
37
2026-Q1
Increased
67,751
+4.3%
$52.3M0.2%$770.59
37
2025-Q4
Increased
64,968
+6.6%
$50.1M0.2%$768.90
37
2025-Q3
Increased
60,964
+3.7%
$34.3M0.2%$559.40
36
2025-Q2
Decreased
58,778
-44.7%
$30.9M0.2%$521.53
0
2025-Q1
Increased
106,217
+2.8%
$67.4M0.4%$629.11
36
2024-Q4
Increased
103,279
+3.9%
$73.6M0.5%$705.67
37
2024-Q3
Decreased
99,417
-45.3%
$104.5M0.9%$1,041.41
0

Other major holders of REGN: FMR LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used